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Progress in the development of immunoanalytical methods incorporating recombinant antibodies to small 
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Malone Road, Belfast BT9 5BN, UK. 
Abstract 
Rapid immunoanalytical screening of food and environmental samples for small molecular weight (hapten) 
biotoxin contaminations requires the production of antibody reagents that possess the requisite sensitivity and 
specificity. To date animal-derived polyclonal (pAb) and monoclonal (mAb) antibodies have provided the 
binding element of the majority of these assays but recombinant antibodies (rAb) isolated from in vitro 
combinatorial phage display libraries are an exciting alternative due to (1) circumventing the need for 
experimental animals, (2) speed of production in commonly used in vitro expression systems and (3) subsequent 
molecular enhancement of binder performance. Short chain variable fragments (scFv) have been the most 
commonly employed rAb reagents for hapten biotoxin detection over the last two decades but antibody binding 
fragments (Fab) and single domain antibodies (sdAb) are increasing in popularity due to  increased expression 
efficiency of functional binders and superior resistance to solvents. rAb-based immunochromatographic assays 
and surface plasmon resonance (SPR) biosensors have been reported to detect sub-regulatory levels of fungal 
(mycotoxins), marine (phycotoxins) and aquatic biotoxins in a wide range of food and environmental matrices 
however this technology has yet to surpass the performances of the equivalent  mAb- and pAb-based formats. 
As such the full potential of rAb technology in hapten biotoxin detection has yet to be achieved but in time the 
inherent advantages of engineered rAb are set to provide the next generation of ultra-high performing binder 
reagents for the rapid and specific detection of hapten biotoxins. 
 
Introduction 
Biotoxins, a structurally diverse group of toxic compounds, are secondary metabolites produced from natural 
origins (e.g. animals, plants, fungi and bacteria) that detrimentally impact on human and animal health. 
Intoxication occurs through consumption of contaminated foods, feeds or from environmental exposure (e.g. 
drinking water) and consequently the detection and quantification of biotoxins is imperative to guarantee the 




been described [1–4] however these methods are often laborious, expensive and are limited in some cases by the 
availability of toxin reference standards. Other methods of detection include functional assays and mouse 
bioassays but these assays have limitations due to specificity as well as ethical concerns with the latter being 
phased out of food safety monitoring [5, 6].  
Immunoassays incorporating sensitive and highly specific biotoxin-specific antibodies offer a rapid, 
inexpensive alternative to the above methods. Immunoassays require antibodies generated by repeated 
immunisations of animals with an antigen, however the success of this approach has been somewhat limited by 
the fact that many biotoxins are haptens i.e. small molecular weight molecules of ≤ 1000 Da that fail to 
stimulate the immune system to produce an antibody response. In some cases even when they are conjugated to 
a larger carrier molecule the complex can fail to elicit an antibody response but can remain highly toxic.  
Furthermore, administration of animals with biotoxins is considered unethical as it may lead to severe adverse 
effects to the animal’s wellbeing and in some cases the limited availability of purified toxin precludes in vivo 
generation of antibodies. Even if successful, the batch-to-batch reproducibility of polyclonal antibodies (pAb) 
can be poor and monoclonal antibody (mAb) development requires highly specialised equipment and labour 
intensive procedures and adequate storage facilities to maintain the hybridoma cell lines.  
 Generation of soluble functional recombinant antibodies (rAb) to haptens from combinatorial in vitro 
antibody libraries has emerged as a promising alternative to in vivo antibody production [7–10].  Advantages of 
rAbs over conventional pAb and mAb include low cost production of functional antibody in commonly used 
expression systems (e.g. bacteria, plants & yeast), high soluble functional protein yields in excess of 10 g/L [11] 
and enhancement of antibody performance by in vitro affinity maturation processes [7].   By mimicking the 
mammalian immune system large repertoires of rAb can be produced to highly toxic haptens in vitro thus 
alleviating the need for animal work.  The focus of this review is to (1) analyse recent progress with the 
generation of hapten biotoxin rAb in the context of rapid screening immunoassays (2) examine the ability of rAb 
to detect sub-regulatory levels of biotoxins in food and environmental samples and (3) highlight future 
potentialities for this field. 
 
Recombinant antibody combinatorial display 
Advances in the field of in vitro combinatorial display technologies have resulted in the generation of a 
plethora of binding molecules to hapten contaminants composed of antibody fragments, nucleic acid aptamers, 




and including 2014, for the topic “recombinant antibody” and “hapten”, excluding review and non-relevant 
articles, returns 343 research articles (Fig.  1) [12]. A further refinement of the search to include the term “phage 
display” yields 64 articles, or yeast-display (9 articles), ribosomal display (5 articles) and 1 article for bacterial 
display. What becomes apparent from Fig. 1 is that the number of articles published in this topic peaked in 1996 
and the lowest number of publications and citations occurred in recent years. However an exhaustive search of 
publications containing the terms ”phage display”, “recombinant antibody” and “hapten biotoxin” compiled 
from Web of Science, PubMed, Science Direct and Google Scholar indicates that the field peaked in 2008 (5 
publications) but still remains active in 2013-2014 (4 publications in each year) and consequently publications 
in this field will be reviewed herein. 
 
Phage display-derived recombinant antibodies 
Phage display technology is an in vitro screening technique for identifying ligands for proteins and 
other macromolecules through the ability to express peptide or protein sequences as fusions to the coat proteins 
of a bacteriophage (viruses that infect bacteria).The ability to insert foreign proteins onto capsid proteins 
without affecting infectivity [13] has seen phage display develop into the most popular in vitro combinatorial 
approach in designing new drugs, vaccines and diagnostics. Phage rAb display has in many cases superseded 
mAb hybridoma technology through creation of highly diversified natural and synthetic in vitro repertoires of 
antigen binders.  Antigen-specific rAb-displaying phage are isolated and enriched through a process of affinity 
selection also known as biopanning (Fig. 2A) and the clones of interest are then amplified in specialised E. Coli 
host cells and enriched by further rounds of biopanning yielding a population of antigen-specific monoclonal 
rAb.  
 Entire antibody immunoglobulin molecules are in most cases too large to be expressed on phage 
surfaces  without negatively impacting on infectivity but smaller antibody fragments such as short-chain 
variable fragments (scFv) and the antigen-binding fragment (Fab)  (Fig. 2B) can be efficiently displayed on 
virion particles [8, 14–17].   The variable heavy (H) and light (L) chains of these antibody fragments, like the 
parent antibody, are comprised of three areas of high sequence diversity called complementarity determination 
regions (H and L CDR1-3) and the CDRs on each chain are connected by stretches of relatively conserved 
sequence which acts as a molecular scaffold called the antibody framework [17].  Of these CDR, the H CDR3 is 




binding specificity [18].  Despite the widespread use of scFv, a major limiting factor of this technology is the 
low functional yields when expressed in vitro principally due to intracellular protein aggregation [19].  
Single domain antibodies (sdAb) or nanobodies such as the Camelidae VHH and shark IgNAR (Fig. 
2B)  possess superior physicochemical stability and high refolding capacity  compared to their scFv counterparts 
[20–22]. Consequently sdAb are produced in soluble functional form in higher quantities from heterologous in 
vitro expression systems and are more resistant to denaturation and solvent-induced conformational unfolding 
[22].  The exceptional stability and solubility is due to (1) the small size of sdAb (11-15 kDa) compared to scFv 
(27 kDa), (2) the single domain nature of sdAb and (3) the evolutionary replacement of non-polar residues 
where the VL interface would be in a scFv with more hydrophilic residues.  The small size and lack of VL of 
sdAb is compensated for by paratopes with greater sequence and topological diversity than scFv/Fab which 
serve  to enhance the binding interface and sequence heterogeneity in the CDR regions involved in antigen-
binding [23]. For example sdAb paratopes have the ability to produce much longer H CDR3 regions than for 
other mammalian antibodies and these finger-like antigen-binding sites are conformationally constrained by 
additional inter-CDR disulfide bonds [24–26]. These enlarged CDR3 regions can form convex  protrusions in 
addition to the planar and concave (cavity) topologies of conventional antibodies [25, 27]. Hapten-scFv 
interaction occurs within a cavity formed between the VH and VL domains of an antibody and as sdAb lack 
these domains they might not be expected to bind strongly to haptens [22]. However, analysis of the crystal 
structure of a nanomolar affinity llama VHH interacting with its hapten antigen (azo dye Reactive Red; 728 Da) 
demonstrated that the hapten was indeed buried in a cavity composed of residues of the three CDR and in 
particular an elongated CDR3 [28, 29]. Moderate affinity  hapten-specific VHH have since been isolated from 
immunised (nanomolar) [24] and naïve (micromolar) [30] phage VHH repertoires. 
 
Detection of haptens using recombinant antibodies 
Aspects of hapten-binding recombinant antibodies has been extensively reviewed in recent years [7–9, 
22] and as a consequence where possible we will focus on more recent case studies..   
 
Antibody engineering 
In vivo-derived antibody affinity for haptens is generally limited (estimated to be 10-10 M or below 




libraries offer more promise as a platform to generate high affinity hapten-recognition molecules than 
conventional antibodies because the phenotype (rAb) is directly linked to the genotype (gene encoding rAb), 
and as such, a rAb affinity can be rapidly enhanced in vitro by antibody engineering processes that mimic in 
vivo affinity maturation [7, 33].  The maximum affinity generated in vivo is believed to be in the sub-nanomolar 
range (KD > 0.1 nM) whereas in vitro antibody engineering processes can result in affinities in the picomolar-
femtomolar range [34] Another way genetic engineering processes can enhance rAb performance is by 
genetically fusing the detector label (e.g. alkaline phosphatase) directly to the rAb [35–37] or indirectly via 
affinity tags or other site-specific moieties [38, 39]. Furthermore, monomeric rAb can be genetically engineered 
into  multimeric high avidity components or domains with differing antigen specificities that can be combined to 
create oligo-specific reagents that retain the sensitivity and specificity of the monomer [16, 26, 40]. Fusing 
several copies of a single sdAb to a pentamerisation domain such as E. Coli verotoxin B subunit has been 
reported to improve avidities several orders of magnitude greater than their monomeric counterparts [41–43].  
    
Naive synthetic recombinant antibody libraries 
Phage displayed rAb libraries can be categorised as either immunised or un-immunised (naïve) 
repertoires and the latter are further classified as natural, semi- or fully synthetic. Immune libraries are 
commonly created from the antibody genes (e.g. VH, VL or VHH) cloned from hybridomas or lymphocytes of 
animals previously immunised with the antigen of interest [14, 51]. Use of immune libraries to generate rAb to 
haptens has been extensively reviewed elsewhere [8] and the merits of this approach are outlined in Table1.  
In general the larger and more diverse the antibody repertoire (number of B cells in vivo or library rAb 
diversity in vitro, the greater the probability of generating a high affinity antibody to a particular target [52]. In 
vivo antibody diversity is estimated to be in the 108  (mice)  to 10 12-15 (humans) range [53–55].  Larger and 
more diverse antibody repertoires may give rise to higher affinity antibody fragments to a wider array of target 
molecules. Strategies used to synthetically construct naive (antibody repertoire constructed without prior 
immunisation with target antigen) libraries with enhanced antibody diversity are reviewed in more detail 
elsewhere [33] but include recombination of V-genes or CDR from different antibody germ lines, modification 
of antigen-interacting (in particular CDR3 H) and antibody framework residues on conserved antibody scaffolds 
[17].   This creates semi-synthetic (elongation of naturally occurring VH and VL genes only) [55] or fully 




enhanced rAb diversity and size compared to the limited natural repertoire (Table1).  Currently rAb synthetic 
library antibody diversity is limited to the 1010-11  range with the principal bottlenecks being transfection 
efficiency of the host and loss of rAb functionality due to frame shift mutations [33].  
The limitations of synthetic naive libraries can be overcome by using synthetic rAb repertoires derived 
from known hapten-binding paratopes. A hapten-binding paratope is shaped as a pocket or cavity with contact 
residues located centrally whereas binding sites for larger molecules are more planar or concave with additional 
contact residues located on the periphery [56]. So-called hapten-“biased” or –“focused” scFv phage libraries 
have been constructed by engineering diversity into antigen-interacting as well as some peripheral or buried 
residues of an existing hapten-binding scFv resulting in isolation of scFv possessing nanomolar affinity to un-
related haptens (Table 2) [57, 58]. Another advantage to these hapten-biased libraries is that the antigen-
interacting residues are optimised for binding to soluble haptens so are expected not to interact with large carrier 
protein molecules frequently used for affinity selection [57].  The efficacy of this approach is highlighted by the 
observation that hapten-biased libraries with a relatively low rAb diversity (e.g. 10 7 library size) generated 
between 50-100% scFv that recognise soluble haptens compared  to a conventional synthetic repertoire which 
generated no such clones [57]. It must be noted that many of the commercially available rAb libraries are 
expensive and often subject to licensing agreements and some companies only offer in-house custom rAb 
production. Table 2 gives an overview of a selection of (semi-) synthetic rAb-based phage display libraries that 
have been reported to generate hapten-specific rAb. 
 
Progress in the detection of hapten biotoxins using recombinant antibody-based assays. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
rAb-based immunoassays to microcystins [77], aflatoxins  [78] and other biotoxin haptens [79, 80] have 
been reviewed previously and so are not discussed in this section but are summarised in Table 4. In order to 
determine the true affinity of an antibody for hapten binding, direct competitive (free hapten to be measured 
competes in solution with hapten labelled with an appropriate detector label (e.g. horse radish peroxidase (HRP) 
for immobilised antibody), or, indirect competitive assay (hapten to be measured inhibits primary antibody 
binding to immobilised hapten and level of primary antibody binding is measured with a secondary anti-species 
antibody coupled to a detector label) are  the most commonly employed approaches. In both cases the amount of 




 A direct competitive ELISA (c-ELISA) incorporating the QY1.5 scFv produced from an anti- 
zearalenone (ZEN) mAb  [81] was immobilised to the plate surface via an affinity tag (E tag) capture antibody 
and free ZEN competed with a ZEN-HRP conjugate for scFv binding.  QY1.5 scFv was previously found to 
possess similar ZEN-binding affinities to the parent mAb in buffer (Table 4) but exhibited enhanced relative 
cross reactivity (between 2- to 7-fold change) to the hydroxylated ZEN analogues [82] (Table 5) however it was 
inactivated when solvent employed for ZEN extraction exceeding 20% v/v. The ability of QY1.5 c-ELISA and 
ic-ELISA  [82] to detect ZEN in spiked corn samples (500-3000 ng ZEN/g corn) was evaluated compared to the 
parent  mAb [83]. The QY1.5 assay detection limits were 4 ng/ml (275 ng/g corn) with ZEN recovery rates of 
95-113% by c-ELISA and 15 ng/ml (1000 ng/g corn) and recovery rate of 100-121% by ic-ELISA although the 
former format was found to be even more susceptible to solvent destabilisation than the latter.  The mAb-based 
c-ELISA was 10-fold more sensitive to ZEN in maize than the equivalent scFv format which is most likely due 
to solvent destabilisation of QY1.5.  The QY1.5 c-ELISA compared favourably to a commercial mAb-based ic-
ELISA in detecting ZEN artificially contaminated wheat samples (97% correlation to Neogen Veratox ELISA 
(n=30)) and detected ZEN in naturally contaminated Chinese wheat samples [84] however no analytical method 
(e.g. HPLC or LC-MS) was employed to confirm the presence of ZEN or its metabolites therein.  Both QY1.5 
ELISA formats possessed sufficient sensitivity to detect sub-regulatory limits of ZEN in cereals in many 
countries as the maximum tolerated limits are set very high (e.g. 1000 µg/kg) (Table 5) however this is not the 
case in Europe where the maximum permitted levels of ZEN in processed maize are 350 µg/kg [85].  Extraction 
of ZEN from foods and cereals requires high concentrations of solvents (e.g. 70% methanol [86]) and as such 
the QY1.5 solvent susceptibility is a major limitation of these scFv-based immunoassays meaning samples have 
to be diluted pre-screening to reduce solvent concentrations resulting in a loss of assay sensitivity. This 
deleterious effect may be overcome by genetically engineering a more stable antibody fragment or alternatively 
the scFv could be replaced by the more solvent-resistant sdAb [22, 87]. A bi-specific binding molecule was 
produced by cloning of the genes encoding QY1.5 and an anti-deoxynivalenol (DON) scFv [88] onto a single 
expression plasmid.  The subsequent divalent scFv maintained the affinity of the monovalent forms for their 
respective toxin and was able to detect DON or ZEN as equally well as the monomers in naturally contaminated 
wheat samples [89].   
An aflatoxin B1 (AFB1)-specific scFv (clone C4) containing an affinity tag (FLAG tag) was used to 
develop an ic-ELISA where detection of scFv binding to solid phase AFB1-BSA conjugate was done using an 




reproducible linear range from 98-1560 ng/ml free AFB1 in PBS with a final methanol concentration of 2.5% 
v/v and the rAb displayed an impressively high level of cross reactivity to seven closely related aflatoxins 
(Table 5).  However scFv stability at the high solvent concentrations (70% methanol [91]) required to extract 
AFB1 from foods was not examined. 
  The first recombinant Fab fragment to hapten biotoxins was produced to detect a lipophilic polyether 
ciguatoxin (CTX) neurotoxin produced by the marine dinoflagellate Gambierdiscus toxicus. Generation of 
CTX-specific antibodies has proved challenging due to its potent toxicity, poor immunogenicity and the limited 
availability of purified natural CTX.  This latter problem has been somewhat overcome by using chemically 
synthesised CTX fragments as immunogens [92].  One such synthetic hapten representing the first three rings 
(ABC) of the left-hand side of the CTX congener CTX3C (CTX3C-ABC) was synthesised, and used to 
immunise mice in order to produce phage-derived recombinant Fab from murine splenic RNA [93]. An ic-
ELISA in which the Fab competed with free CTX synthetic fragments (0.001-100 µM) or natural toxin 
(concentrations not published) for binding to a CTX3C-ABC protein conjugate passively coated microtiter 
plates. The affinity of the Fab clone 1C49 ELISA possessed moderate affinity for the free ABC synthetic 
fragment (8.6 x 10-8 M KD) but considerably weaker affinity to the free ABCD fragment (2.4 x 10-5 M KD) and 
the natural soluble CTX3C.  The authors failed to publish the affinity of Fab 1C49 for free CTX3C but 
interpretation of the published results suggests that the KD was approximately 1.3 x 10-5 M. Crystal structure 
analysis of 1C49 interacting with CTX indicated that the ABC fragment was deeply buried within the Fab 
antigen-binding pocket suggesting that the ABCD fragment and the polyether CTX3C were sterically hindered 
from binding to the paratope  [94]. Antibodies with extremely high affinity for CTX are required for rapid 
screening of fish samples as trace amounts (parts per trillion [95]) of CTX can elicit toxicity and recent studies 
by the same group have determined that a minimum pentacyclic CTX synthetic fragment immunogen is required 
to produce mAb-based sandwich ELISAs that recognise ppb (nM) amounts of CTX in buffer [96–98] although 
no rAb derived from these mAbs have been published to date. Analysis of rAb produced from these hybridomas 
would be of interest and possible further enhancement of sensitivity by in vitro affinity maturation processes to 
generate rAb possessing the ultra-sensitivity required to detect CTX would be an exciting option to explore in 
the future. 
Hu et al produced a scFv from the RNA of a hybridoma secreting an anti-domoic acid (DA) mAb and 
investigated several parameters (domain orientation, linker length, accessory protein co-expression & 




was compared to the parent mAb in an ic-ELISA where antibody competed with free DA (concentrations not 
published) for binding to a DA-ovalbumin (OVA) conjugate coated on a microtiter plate. The amount of 
antibody binding to the solid phase DA was detected by addition of an appropriate HRP labelled anti-species 
secondary (mAb) or an anti-His tag (scFv) antibody. The 2H12 scFv ELISA was approximately 4-fold more 
sensitive than the parent mAb (Table 4) and although the 2H12 scFv possessed sufficient sensitivity in buffer to 
detect sub-regulatory amounts of DA in fish samples no assessments were performed in such samples.  Another 
group used a sheep hyper-immunised with DA-BSA conjugate to generate an immune scFv phage library from 
which scFv clone DA24cB7 was isolated and used to develop an anti-DA ic-ELISA [100]. A calibration curve 
was constructed using the mean of 19 separate experiments over a 6 week period with free DA standards (00.63-
80.3 nM) and the scFv ELISA was reported to be highly reproducible (although %CV not published) with a 
linear working range of 0.30 ng/mL to 5.58 ng/mL (calculated using the IC10 & IC80 values) with an LOD of 
0.5 ng/ml (IC20 value). The scFv ELISA correlated well (R2 =0.91) to HPLC analysis of 50% methanol 
extracted DA from naturally contaminated shellfish extracts although the ELISA was found to underestimate the 
results. The authors rectified this by setting a cut off value (15 mg/kg) just under the regulatory limit of 20 
mg/kg (Table 5) which resulted in identification of all the HPLC-positive extracts. There are two reasons why 
the DA24cB7 scFv assay was more sensitive than the murine 2H12 format described above or another affinity 
matured DA-specific scFv (clone R4Sh-7)  produced from an immunised chicken [101] (Table 4) which are (1) 
the species chosen to produce a DA-specific immune response and, (2) the superior affinity selection strategy 
used to isolate DA24cB7 (successive rounds of biopanning with reduced target hapten concentration favours the 
isolation of high affinity scFv). However one note of caution with all three anti-DA scFv produced to date is that 
the cross reactivity profiles to other marine biotoxins that may occur in shellfish samples was not reported. 
In 2009 three more reports of AFB1-specific scFv ELISAs were published and in the first case, Wang 
isolated scFv with affinities of 0.4-0.7 µg/ml in buffer as determined by ELISA [102]. In the second report the 
authors wanted to avoid the biased immune response towards hapten derivatives and non-relevant protein carrier 
molecules used in immunisation protocols and instead directly coated AFB1 to the biopanning surface [103]. 
scFv clone H4 was isolated following affinity selection against the soluble target  and incorporated into an ic-
ELISA that possessed the highest affinity for free AFB1 in buffer described to that date (Table 4) and exhibited 
some cross reactivity to other aflatoxins (AFG1 (42%)>AFB2 (12%)> AFG2 (9%)).  The bacterial expression of 
soluble functional clone H4 scFv was subsequently optimised to maximise the rAb yield [104].  In the third 




B lymphocytes of 140 non-immunised human donors [61]. A soluble AFB1-specific scFv (YM1-C3) was 
isolated from the Yamo-1 library which was genetically fused to an alkaline phosphate (AP) detector label (in a 
1:1 ratio) [105].  Direct fusion of the AP to scFv (YM1-C3-AP) resulted in a 3-fold increase in sensitivity to free 
AFB1 in a single-step ic-ELISA when compared to the unlabelled scFv assay (Table 4). The relative cross-
reactivity of the scFv-AP fusion products to closely related aflatoxins as determined by the ELISA was reported 
(AFG1>G2=B2>>M1). The authors attributed the success in generating high affinity scFv from the Yamo-1 
library due to prior exposure of some of the human donors to aflatoxins. 
Non-competitive assays such as the sandwich ELISA require a pair of antibodies with epitopes on 
different parts of the target antigen, an unlikely possibility when measuring small molecules. The development 
of “open sandwich-immunoassay” (OS- ELISA) has somewhat circumvented this problem by exploiting the 
antigen-mediated association of the VH and VL when expressed as separate entities [36].  Hara et al described 
the development and validation of a non-competitive OS-ELISA to detect the paralytic shellfish poisoning 
(PSP) biotoxin gonyautoxin (GTX2/3) [106].  A GTX2/3-specific mAb (GT-13a) [107] was used to produce a 
GTX-specific Fab from which the VH and VL domains were expressed as different soluble protein entities 
fused to maltose-binding protein (MBP-VH) or MBP plus affinity tag (MBP-VL-c-myc). The MBP-VH was 
coated onto the microtiter plate and upon the concomitant addition of free toxin and MBP-VL-c-myc an antigen-
driven association of the two chains occurs. The amount of GTX-VH-VL complex present was measured using 
a c-myc-specific HRP-labelled secondary antibody. The Fab OS-ELISA performed similarly to previously 
described parent GT-13a competitive mAb-based immunoassays (albeit these assays used the parent PSP 
biotoxin saxitoxin (STX) as target ligand) [107–109] exhibiting the highest affinity for the immunogen used to 
produce the mAb (GTX2/3 0.28 ng/ml IC50) slightly less so for STX (4 ng/ml IC50) and, similar to other 
competitive pAb-based assays [110],  minimal cross reactivity  to hydroxylated analogs.  The linear range of the 
OS-ELISA (0.05-300 ng/ml) was three orders of magnitude wider than those reported for the other GT-13a 
mAb-based assays and was capable of detecting four PSP toxins (GTX2/3, STX, C1/C2 and dcGTX2/3) in 
shellfish extracts artificially spiked at the regulatory limit of 800 µg PSP equivalents/kg shellfish meat [111, 
112] (Table 5).  OS-ELISA typically exhibit lower limits of detection, a broader working range and superior 
assay precision for hapten molecules (e.g. ZEN , estradiol (17β-E2) and corticosteroid (11-DC)) when compared 
to the equivalent competitive formats [36, 113–115]. One note of caution with the OS-IA format is the high-




be reduced by site-specific mutations at the VH-VL interface [115] or prior in vitro combinatorial screening for 
compatible V chains (OS selection) [116, 117].   
Huovinen et al modified a naïve synthetic mouse library designed for binding macromolecules (ScFvP) 
by introducing sequence diversity deep in the paratope and blunting CDR-H3 loops they managed to introduce a 
bias towards hapten binding [118]. A microcystin (MC LR)-specific scFv (clone M-MCLR1) from the resultant 
phage library (ScFvM) was isolated and incorporated into a competitive time-resolved fluorescence-based 
immunoassay (TRF-IA)  consisting of free microcystin  competing with  a MC LR tracer labelled with the 
fluorescent lanthanide  Europium for binding to the M-MCLR1 captured on the ELISA plate by an anti-mouse 
antibody. The authors acknowledged that they chose MC LR as a prototype peptide hapten target to validate 
their library performance and as such didn’t examine the cross reactivity profile to other microcystins or validate 
the ELISA using environmental samples. The nanomolar affinity of the scFv assay (Table 4) was most likely as 
a result of the lanthanide fluorescent label employed possessing sensitivities at least 10-fold greater [119] than 
colorimetric or chemi-luminescent labels commonly employed in ELISAs and it would be interesting to 
compare the performance of M-MCLR1 scFv to a conventional Ab using the same detector label.  
The first AFB1-specific Fab-based ic-ELISA was used to compare the merits of an AFB1 derivative 
covalently coupled to a polystyrene plate to passively adsorbed AFB1-BSA on the same surface [120]. The 
sensitivity of the covalent AFB1 assay was 2.7-fold greater than that of the BSA-AFB1 format  in buffer (Table 
4) and in both assays Fab were specific for AFB1 with some cross reactivity observed to AFG1 (Table 5) and no 
recognition of unrelated co-occurring mycotoxins tested (ZEN, DON and T-2 at 10 µg/ml). The covalently 
linked AFB1 assay permitted a shorter primary antibody incubation time, was more resistant to methanol (up to 
40%) and could be re-used 4 times upon treatment with chaotropic agents  (89% agreement in IC50 over 
successive uses) when compared to passively coated BSA-AFB1. The covalent Fab-AFB1 assay was matrix 
validated by measuring AFB1 in 40% methanol extracted from reference corn material containing AFB1 and 
AFB2 [120]. The assay was robust (<5% intra- and inter-day variation) but the authors failed to report the % 
recovery of AFB1 from the reference matrix or the side-by-side performance of the passively adsorbed AFB1-
BSA ELISA with corn. Another interesting point would have been to compare the performance of ELISAs 
utilising the Fab to those incorporating a conventional antibody or the previously described scFv produced by 
the same group [121]. To overcome scFv inactivation at high methanol concentrations commonly used to extract 
aflatoxins (70-80% v/v) [91] an immune sdAb (VHH) phage display library was constructed from blood 




isolated by affinity selection from the library with soluble hapten elution and VHH clone Nb26 exhibited high 
sensitivity (0.75 ng/ml IC50) to soluble AFB1 with a broad working range (0.117−5.676 μg/kg) in buffer and 
was specific to free AFB1 (10.1% relative cross reactivity to AFM1).  
In addition to AFB1, other aflatoxins are harmful on their own and monitoring of the sum of aflatoxins 
(AFB1+B2+G1+G2) is also essential to limit the total aflatoxin content of food and foodstuffs [122, 123]. With 
this in mind Edupuganti et al produced AFB2-specific rAbs from a scFv-phage library produced from the 
splenic RNA of mice immunised with AFB2-BSA [124]. AFB2 is the dihydroxy derivative of AFB1 which 
albeit has reduced toxicity than AFB1 is present in trace amounts in foods and feed but has a lower 
susceptibility to decontamination methods than AFB1.  Two clones were found to be highly specific to AFB2 
when screened by ic-ELISA (Table 5) and the more sensitive clone (E9) (85 ng/ml IC50 in buffer) and was 
incorporated into a SPR-based assay for further analysis (next section).  In another study Zhang et al produced a 
series of high affinity mAbs using AFB1-BSA immunogen with a range of diverse cross-reactivity profiles that 
possessed high affinity to either total aflatoxins (clone 1C11; AFB1+B2+G1+G2 at 1.2-18.0 pg/ml IC50) or 
AFM1 alone (clone 4F3; 0.27 ng/ml IC50) [125]. The same group subsequently constructed a phage scFv 
library composed of the VH and VL of almost 20 hybridomas secreting mAbs (including clones IC11 and 4F3) 
with diverse specificity to aflatoxins [126]. From this immunised repertoire two scFv of interest were rapidly 
isolated (without biopanning) and incorporated into ic-ELISAs. The first scFv clone (2G7) was found to possess 
the highest reported sensitivity to free AFB1 to date (0.01 ng/ml IC50 in buffer) and was highly specific to 
AFB1. The second clone (1A7) also exhibited excellent affinity to AFB1 (0.02 ng/ml IC50 in buffer) but also 
strong cross reactivity to AFB2 (166%), AFG1 (100%) and to some extent to AFM1 (11%). It is worth noting 
that the scFv clones of interest were isolated according to their ability to recognise AFB1 and as such it may be 
possible to select scFv candidates exhibiting different cross-reactivity profiles by using more appropriate target 
ligands.  Cows can metabolise AFB1 into AFM1 whose levels in dairy products are regulated for raw milk and 
infant formulas at 0.05 and 0.025 ppb respectively [122] and as the immune library potentially contains 4F3 
antibody fragments that exhibit ppb sensitivity for AFM1 it should be possible to isolate high affinity scFv by 
screening with AFM1 target ligand. 
Detection of the hepatotoxic microcystin (MC) congeners, other than MC-LR, is of critical importance 
and animal-derived pan-specific antibodies have been raised against the invariant toxic Adda amino acid ((3-




has been described [127, 128]. 3-D structural modelling an anti-MC LR scFv 3A8 [129] (Table 4) binding to 
MC LR identified the Adda residue as the most likely epitope for this rAb which seemed to be confirmed 
somewhat by an scFv-AP conjugate dose-dependent binding to an Adda mimic by ELISA [130]. In the same 
report, real-time SPR analysis of the scFv-AP binding directly to immobilised MC-LR-OVA seems to have 
identified a possible flaw with some scFv as two binding affinities were detected (KD1 = 0.22 nM & KD2 = 8.73 
μM) suggesting the presence of a heterologous population (either mis-folded or aggregated scFv). This 
observation was borne out by the relatively weak affinity of the 3A8-AP for free MC-LR in a one-step ic-ELISA 
((IC50 =2.97 µM & LOD (IC10) of 0.25 µM in buffer). This work very elegantly highlights the need to fully 
characterise monoclonal scFv in order to ensure the presence of a single homogenous functional rAb population 
and suggests the greater potential of the more thermostable sdAb which are less prone to mis-folding. 
A Chinese group recently developed a scFv-based ELISA to measure the carcinogenic mycotoxin 
fumonisin B1 (FB1) found in contaminated corn samples [131]. The scFv was cloned from a hybridoma 
expressing an anti-FB1 mAb (1D11) and ic-ELISA analysis showed that the scFv performance was very similar 
to the parent mAb. Both antibody ELISAs possessed similar affinity to FB1 in buffer (Table 4) and were 
specific to FB1 with less than 10% cross reactivity to the closely related FB2 and no recognition of other co-
occurring unrelated mycotoxins (Table 5) although the scFv ELISA linear range (2.1-76.45 µg/L) was 
marginally higher than that of the parent 1D11 (1.67-61.74 µg/L). The scFv assay successfully validated in corn 
samples according to the criteria set out by the European Commission Decision 2002/657/EC [132]. The 
analytical limit calculated from 20 known blank corn samples ranged from 1.40 to 6.30 µg kg−1 due to the crude 
nature of the matrix and LOD (8.32 µg/kg) were calculated from the same corn samples spiked with known 
concentrations of FB1 with intra- (9.72-10.26 %CV) and inter-assay (11.28-14.03 %CV). Furthermore the scFv 
ELISA displayed good agreement (R2 = 0.97) to HPLC analysis of 30 naturally FB1-contaminated corn 
samples. Council Directive 2002/657/EC [132] established criteria and procedures for the validation of 
analytical methods to ensure the quality and comparability of analytical results generated by official laboratories 
and established common criteria for the interpretation of test results. One of the requirements is that the 
detection capability (CCβ) (15 µg/kg) must be less than or equal to the regulatory limit set which worldwide 






Immuno-biosensors enable the real-time analysis of antigen-antibody interactions which is subsequently 
detected by a transducer or sensing device  (e.g. optical, electrochemical, acoustical, piezochemical or 
micromechanical [141]).  Optically-based BIAcore instruments are a widely used example of biosensors which 
enables biospecific interaction analysis (BIA) of antigen–antibody binding with high sensitivity and speed of 
analysis. The BIAcore technology utilises the phenomenon of surface plasmon resonance (SPR) where one 
interacting molecule (ligand) is bound to the biosensor surface (flow cell on sensor chip) while the other 
(analyte) is delivered to the surface in a continuous flow through a microfluidic system [9, 110, 141].  This 
technology also offers the advantage of real time analysis of antibody-antigen interaction kinetics (e.g. 
association (KON) and dissociation rate (KOFF) constants) and requires no labelling of biomolecules. SPR 
depends on a change in mass when an antigen binds to an antibody and as hapten analytes are too small to 
measure a significant change in mass by direct binding, competitive assay formats are usually employed  [110]. 
This format requires the immobilisation of the biotoxin-specific antibody to the chip surface which can in many 
cases be problematic [142] and so the majority of SPR–based assays to measure haptens employ the competitive 
format. The ic-SPR assay is based on the same principle described previously for the ic-ELISA where the 
analyte to be measured is incubated with antibody before injecting the mixture over the immobilised target 
ligand (low molecular weight biotoxin either as a free derivative or coupled to a carrier macromolecule) and the 
amount of biotoxin present in a sample is inversely proportional to the level of antibody binding. One caveat of 
ic-SPR is that the competing antibody must possess moderate affinity for the immobilised hapten (in other 
words possesses a relatively fast dissociation rate (KOFF)) so as the chip can be completely regenerated with 
relatively weak agents thus permitting a higher number of binding-regeneration cycles. 
The first reported study of incorporation of a hapten biotoxin-specific rAb into an immuno-biosensor 
was by Moghaddam who wanted to address the difficulties in obtaining scFv capable of distinguishing  soluble 
hapten over those generated towards the carrier protein and/or derivatised hapten immunogen [73]. They 
compared the efficacy of isolating  scFv specific to free AFB1  from either a naïve human pooled lymphocyte-
derived repertoire [143] or a hapten-biased semi-synthetic library [58]. The latter approach yielded the most 
success in isolating scFv to free AFB1 but only when hapten elution of the scFv-phage during biopanning was 
employed.  A purified AFB1-specifc scFv (Afla-45) was characterised by ic-SPR using a BIAcoreX biosensor 
wherein Afla-45 was pre-incubated with a range of concentrations of soluble AFB1 (0.5-4000 nM 
corresponding to 0.25 to 100 times Afla-45 concentration) or other mycotoxins (60 nM) and subsequently 




BSA signal generated was subtracted from that of the AFB1-BSA and the heterogeneous ligand-binding model 
was used to analyse scFv binding kinetics. Afla-45 exhibited nanomolar affinity to free AFB1 (Table 4) in 
buffer and recognised AFG1 equally well but not M1 or M2 or the unrelated ochratoxin A. The authors used 
AFB1 as a model antigen to demonstrate that a hapten-biased scFv library possessing specificity for one hapten 
(phOx) can be modified by rationale design to generate high affinity binders to other structurally unrelated 
haptens and as such no validation of Afla-45 performance in food samples has been undertaken to date (personal 
communication). 
The AFB1-specific clone C4 scFv characterised by ELISA in the previous section was purified by 
immobilised metal affinity chromatography (IMAC) and incorporated into an BIAcore-based ic-SPR where a 
series of dilutions of AFB1 (0-195 ng/ml)  where incubated with the rAb before injecting the mixture over a 
CM5 flow cell containing AFB1-BSA [90]. Multiple regeneration steps with high pH solution (10 mM NaOH) 
of the freshly immobilised conjugate ensured only stably coupled AFB1-BSA remained on the chip resulting in 
consistent binding responses over 50 cycles of sampling and non-specific binding of the scFv to a flow cell 
immobilised with BSA alone was negligible.  The working range in buffer was determined to be between 3-195 
ng/ml free AFB1 and the assay possessed acceptable accuracy and precision (intraday CV% 0.1-16.5 & interday 
CV% 3.7-11.8). Most interestingly the assay was more sensitive in detecting AFB1 in spiked grain samples than 
in buffer exhibiting a LOD as low as 0.75 ng/ml (detection range = 0.75-48 ng/ml). The clone C4 scFv assay, 
unlike Afla-45 scFv, exhibited a superior cross-reactivity profile (in particular recognises both AFM1 and 
AFM2) and was able to detect sub-regulatory amounts of AFB1 in corn (Table 5). The same group described a 
BIAcore inhibition SPR-based assay incorporating either a monomeric or dimeric AFB1-scFv where 
immobilised AFB1 derivative as target antigen was employed instead of a protein conjugate [121]. The reason 
for this change in immobilised ligand was due to difficulties encountered in regenerating the BSA-AFB1 chip. 
Studies revealed that a slightly stronger regeneration solution (25 mM NaOH) was required for the complete 
removal of dimer which still enabled over 500 reproducible binding cycles to be completed. The monomeric 
assay had a working range of 0.375-12 ng/ml of free AFB1 in PBS containing 5% methanol and the dimer 
exhibited a slightly broader working range and recovery rates of around 80-110% were described reflecting a 
high degree of assay accuracy and reproducibility at least when screening in buffer.  The scFv displayed a high 
specificity for AFB1 with only slight cross-reactivity to other aflatoxins (AFM1 & AFG1=12.5%). The 




group (linear range 3-98 ng/ml) [144] although the pAb exhibited superior cross-reactivity to other aflatoxins 
(Table 5).  
Hu et al [99] hypothesised that a higher density of the anti-DA scFv 2H12 (27kDa) can be attached to a 
biosensor flow cell surface compared to the larger but lower affinity parent mAb molecule (160-180 kDa) would 
result in an extremely sensitive assay to detect DA in fish samples. The immobilisation characteristics of the 
scFv clone on various mesoporous silicate surfaces [145, 146] and the ability of 2H12 to be genetically 
engineered  to correctly orientate the scFv for optimal antigen binding [147] were subsequently investigated but 
to date no 2H12-based biosensor to measure DA in fish samples or seawater has been described. 
The performance of an AFB1-specific scFv (clone H4 described in previous section) produced by Yang 
was assessed with a BIAcore instrument by pre-incubation with free AFB1 (0-2.0 ng/ml) before injecting over 
an AFB1-BSA chip. The authors claim the ic-SPR assay possessed similar affinity (IC50) to the ic-ELISA 
mentioned previously but didn’t publish the value however the KD for soluble AFB1 in buffer was determined 
using the Langmuir 1:1 model to be 1.2 x 10-12 M.  A scFv isolated from an immunised phage library using an 
AFB1-specific mAb (2C12) as a template [139] was highly-specific for AFB1 and unable to recognise any other 
unrelated mycotoxins (OTA, FMB1, FMB2, DON and T-2 toxin) tested by ELISA. The scFv affinity for free 
AFB1 in buffer (Table 4) was approximately 17-fold lower than that of the parent mAb. The anti-AFB2 scFv 
clone E9 produced by Edupuganti [124] (reviewed in the previous section) exhibited nanomolar affinity (Table 
4) for an immobilised AFB2 derivative using a BIAcore3000 instrument and exhibited marginally higher 
affinity to free AFB2 in buffer (8 ng/ml IC50) than in an almond matrix (11 ng/ml IC50) with acceptable assay 
precision over 5 separate days (CV% <11). 
Lateral flow immunoassays 
Lateral flow immunoassays (LF-IA) are a commonly used example of a micro-fluidic immunosensor where 
flow through of the analyte in running buffer and detector antibody (usually conjugated to colloidal gold for 
visual detection or fluorescent nanoparticles for fluorescent scanner detection) suitable support surface such as 
nitro-cellulose is driven by capillary forces [148]. Following on from the successful isolation of microcystin-
specifc scFv ELISAs from naïve synthetic rAb repertoires [64, 129] (Table 4) capable of detecting MC LR in 
water below the WHO guidelines [149, 150] the same group produced a commercially available scFv-based LF-
IA dipstick (Microcystin kit Immunostrip® (ISK 84300) Agdia Inc., USA). The assay is based on the 




LF-IA was validated using a range of water qualities (distilled, tap or lake water) artificially fortified with seven 
microcystins or the closely related nodularin which were detected at 0.5 µg/l (Table 5). Despite this the 
manufactures recommend a detection threshold of 10 µg/L-1 which enables users to determine if the MC levels 
are approaching the moderate risk guideline value for recreational activity in water of 20 µg/L-1 [150]. The scFv 
LF-IA distinguished toxic from non-toxic cyanobacterial extracts and correlated well with HPLC analysis of 
real life water samples contaminated with harmful algae blooms giving no false positives. The authors did note 
that the dipstick failed to work in brackish water samples which suggests some element of pre-screening de-
salination of these samples would be required in these cases. The first LF-IA published to quantify MC LR in 
water used fluorescently-labelled (Alexa-647) mAb as the detector signal and a portable fluorescent scanner was 
designed to measure the signal [151]. This assay system possessed a higher sensitivity than the scFv-based assay 
(0.05 µg/l LOD in buffer) and the authors also noted a deleterious effect when monitoring low levels of 
microcystins in river water samples albeit at levels over an order of magnitude below the WHO guidelines (MC 
LR concentration < 0.1 ng/l). LF-IA technology is compatible with multi-analyte detection simply by adding 
several lines of immobilised antigen or antibodies with different specificities to the strip and dipsticks 
employing conventional Abs to measure up to six co-occurring Fusarium mycotoxins in cereals  (ZEN, DON, 

















ZEN Immunised (Hybridoma) scFv (QY1.5) ELISA 14 ng/ml (IC50) [82] Comparable affinity to parent mAb but 
enhanced cross reactivity 
2000 




ELISA 4 x 10-6M (IC50) [133] First rAb isolated from naïve synthetic 
phage library 
2001 
ZEN Immunised (Hybridoma) scFv (QY1.5) ELISA 4 ng/ml (LOD) [83] More sensitive than QY1.5 ic-ELISA but 
more susceptible to solvent destabilisation 
AFB1 Human naive 
 
 
scFv (Afla-45) SPR 6 x 10-9 M (KD) [73] Only semi-synthetic library generated high 
affinity scFv 
2002 
MC LR Human semi-synthetic 
(Griffin.1) 
scFv (3A8) ELISA 
 
 
4.5 x10-9 M (IC50) [129] Incorporated into immunoaffinity column 
for concentration of MC LR from water 




ELISA 13 x10-9 M (IC50) [64] scFv 300-fold greater sensitivity than those 














DON Immunised (hybridoma) scFv SPR 3.7×10−6M (KD) [134] scFv affinity weaker than parent mAb 
(8.8 × 10−8 M KD) 
CTX Immunised (mouse 
splenocytes) 
Fab (1C49) ELISA Affinity to natural 
CTX not published 
[93] Fab had weak affinity (10-5 M) for natural 
CTX 
2005 
AFB1 Not published scFv 
monomer/dimer 
SPR 0.375 ng/ml 
(monomer) 
0.19 ng/ml (dimer) 
(LOD) 
[121] AFB1 derivative immobilised on flow cell 
permits over 500 reproducible binding-
regeneration cycles 
DA Immunised (Hybridoma) scFv (2H12) ELISA 245 ng/ml (IC50) 
 
 
[99] More sensitive than parent mAb  (1000 
ng/ml IC50) 
FB1 Human synthetic (ETH-2) scFv (BFB1-02) SPR 4.08×10−7M (KD) [68] scFv specificity for FB1 & FB2 
2006 
DA Immunised (Chicken) scFv (R4Sh-7)   ELISA 156 ng/ml (IC50) [101] scFv affinity-matured to be more sensitive 
than parent pAb (1000 ng/ml IC50) 
2007 
DON Immunised (hybridoma) scFv ELISA 8.2 ng/m(IC50) [88] Equivalent affinity but enhanced cross 
reactivity to DON metabolites of scFv 
when compared to parent mAb  
ZEN Immunised (hybridoma) scFv OS-IA 20 ng/ml (LOD) [113] OS-IA working range (0.1-10 µg/ml) 
broader than that of ic-ELISA (3-0.1 
µg/ml) 
2008 
ZEN Immunised (Hybridoma) scFv (QY1.5) c-ELISA 1 µg/ml [84] Compared favourably to commercial 





ZEN/DON Immunised (Hybridoma) Bispecific scFv 
dimer (QY1.5) 










FPIA 0.5 µM (monomer) 
 1.24 µM (dimer) 
 (IC50) 
[135] Monomer & pentamer affinity comparable 
to parent pAb (1.42µM) 





ELISA 2.6 ng/ml (IC50) [100] Retained  sensitivity of parent pAb (2.8 
ng/ml IC50) 
2009 
AFB1 Human synthetic 
(Tomlinson I) 
scFv ELISA 0.4 µg/ml  [102] Compared four elution conditions and 
found hapten elution/trypsinisation was 
optimal 




0.4 ng/ml (IC50) 
1.2 X 10 -12 M 
(KD) 
[103] scFv stabilised by interdomain disulfide 
bond 
2010 
MC LR Not published scFv LF-IA 0.1-0.5 µg/l [137] Commercially available scFv-based lateral 
flow device for detecting microcystins and 
nodularin 
FB1 Immunised (Hybridoma) scFv ELISA Not reported [138] Parent mAb possesses 12-fold greater 
affinity (10 ppb LOD & 220 ppb IC50) 
2011 
AFB1 Human naïve 140 human 
donors 
scFv ELISA 0.12 µg/ml (YM1-
C3) 
[105] Direct fusion to alkaline phosphatase (AP) 










AFB1 Immunised (hybridoma) scFv SPR 1.16 × 10−7 M (KD) [139] Parent mAb 17-fold better affinity (6.95 x 
10-9M) then scFv  
2012 
MC LR Murine naïve synthetic  Fab TRFIA 0.435 µg/ml 
(IC50) 
[140] MC-LR scFv rapidly isolated from mouse 
naïve library analysed by time-resolved 
fluorometry 
2013 
GTX2/3 Immunised (Hybridoma) scFv OS-
ELISA 
0.05 ng/ml (LOD) [106] Wider working range of OS-ELISA (0.05-
300 ng/ml) compared to equivalent ic-
ELISA (0.7-130 ng/ml) 




c-TRFIA 23 nM (IC50) [118] MC-LR scFv rapidly isolated from mouse 
naïve library analysed by time-resolved 
fluorometry 
AFB2 Immunised (mouse 
splenocytes) 
scFv (E9) ELISA 
SPR 
3 ng/ml (LOD) 
0.9 ng/ml (LOD)  
[124] scFv–SPR biosensor capable of detecting  
sub-regulatory levels of AFB2 in 
artificially contaminated almonds 
AFB1 Not published Fab ELISA 27 ng/ml (IC50) [120] Sensitivity of AFB1 covalent immobilised 
to microtiter plate was 2.7-fold greater than 
that of passively coated AFB1-BSA assay 
(77 ng/ml IC50) 
2014 





AFB1 Immunised (Pooled 
hybridoma) 
scFv (2G7) ELISA 0.01 ng/ml (IC50) [126] Developed a scFv capable of measuring 
total aflatoxins 
MC LR Human semi-synthetic 
(Griffin.1) 
scFv-AP (3A8) ELISA 2.97 µM (IC50) [130] Moderate 3A8  affinity due to heterologous 
scFv population 
FB1 Immunised (Hybridoma) scFv ELISA 12.67 µg/L (IC50) [131] Similar affinity (10.16 µg/L IC50)  and 
specificity to parent mAb 
Abbreviations: fluorescence polarization immunoassay (FPIA), open sandwich ELISA (OS-ELISA), affinity constant (Kaff), time-resolved immunoassay (TRFIA), lateral 
flow immunoassay (LF-IA) 






Regulatory Limits Assay format Lowest detected levels 
in food matrix 
Matrix 
tested 
Antibody cross-reactivity (%) Reference 
AFB1 








Fab ic-ELISA 12 ppb (35 ppb IC50) 
 
grain 
AFB2 2, AFG1 18, AFG2 1 [120] 
VHH ic-ELISA 
(clone Nb26) 
3 ppb IC50 Peanut, rice, 
corn, 
feedstuff 
AFB2 1, AFG2 2, AFM1 11 
 
[87] 
pAb c-ELISA 8 ppt Rice, beans 







Total Aflatoxins  (AFB1+B2+G1+G2) but 






cAb-ELISA N/A 1.75 ppb Cereals & 
feed 
Total Aflatoxins   AFB1 100, AFB2 48, 

















scFv ic-SPR  
 (clone C4) 
0.75 ppb 
grain 
AFB2 53, AFG1 76, AFG2 68, AFM1 50, 
AFM2 23, AFB2a 18,  AFG2a 22 
[90] 
 





pAb Ic-SPR 3 ppb 
No 
AFB2 68, AFG1 66, AFG2 50, AFM1 35, 
AFM2 2, AFB2a  33, AFG2a 16 
[144] 
AFB2 






8 -0.9 ppb (µg/kg) 
 Commission et al. 2007) 
 
2 –0.3 ppb 
[158] 
 
scFv ELISA 8 ppb IC50 Wheat 3-Ac-DON 6, 15-Ac-DON 5, Nivalenol < 1, 
T-2 < 1 
[88] 





cAb-ELISA N/A 3.7-18.5 ppb Cereals, 
malt, feed, 
beer & wort 
3-Ac-DON 100, 15-Ac-DON 19, Nivalenol 





pAb ELISA 10-30 ppb Cereals, 
food, feed & 
beer 
3-Ac-DON 96, 15-Ac-DON < 1, Nivalenol 





cAb-ELISA N/A 1 ppm Wheat 
products 







3 - 1 ppm (mg/kg) 
[158] 
 
4 – 2 ppm 
[85] 
 
2 – 4 ppm 
[159] 
scFv ELISA 8 ppb (13 ppb IC50) 
wheat 
FB2 5, AFB1< 1, DON < 1, ZEN < 1, OTA 
< 1 
[131] 
mAb ELISA 10 ppb IC50 FB2 9, AFB1< 1, DON < 1, ZEN < 1, OTA 
< 1 
mAb ELISA 2.2 ppb IC50 maize FB2  154, AFB1< 1, DON < 1, OTA < 1 [160] 
pAb ELISA 0.05 ppb maize FB2 72, FB3 5, AFB1< 1 [161] 
cAb-ELISA N/A 25 ppb Corn & corn 
products 











cAb-ELISA N/A 5 ppb Barley, corn, 
rice, soybean 
& wheat 
Total fumonisins (FB1, B2, B3) but % cross 










VHH ic-ELISA 17-21 ppb (IC50) 
 
Wine, coffee 
OTB 2.5 , L-Phe <1, coumarin <1 [136] 
mAb ic-ELISA 2.5 ppb Cereals OTB 17, AFB1<8.5, FB1 9.4, DON 9.6 [163] 
pAb c-ELISA 10 ppb Soybean, 
cereals, 
corn, coffee 
OTB 0.8 , OTC 167, citrinin <1, L-Phe <1 [164] 





















cAb-ELISA N/A 1 ppb 
Cereals, 
coffee & 






dried fruits Ochratoxin) 
ZEN 
 
1000-50 ppb (µg/kg) 










α-ZEL 82, β- ZEL 26, α- ZAL 62, β- ZAL 
26 
[82–84] 









α-ZEL 107, β- ZEL 29, α- ZAL 35, β- 
ZAL 25 
[86] 
mAb c-ELISA 150 ppm Feed  α-ZEL 101, β- ZEL 121, α- ZAL 122, β- 
ZAL 152 
[165] 



















mAb c-ELISA 25 ppb Corn, wheat, 
barley 







1.0 ppb (µg/L) 
cell-bound or free in 







































pAb ic-ELISA 0.05 ppb Surface/drin
king water 









MC-RR 8, -LW < 1, -LF < 1, -YR 12, Nod 
< 1 
[168] 
cAb-ELISA N/A 0.16-2.5 ppb Surface 
water 





scFv LFD  0.5 ppb Tap, distilled 
& raw water 
MC-RR 100, -LW 500, -LF > 100 -LY > 
100 -D-RR 100 -Me-LR 50 Nod 500 
[137] 
scFv LFD 0.095 ppb Surface 
water 
Cross-reactivity to MC-RR & -YR detected 










800 ppm Shellfish STX 6.4, neo-STX <1 [106] 
mAb ic-SPR  
(GT-13a) 
160 ppm Shellfish dcGTX2/3 111, C1/2 106, STX 95, dcSTX 
79, GTX5 97, daSTX 49, dhSTX 75, 






mAb MS-FC  
(GT-13a) 
260 ppm Shellfish dc-GTX2/3 100 , C1/2 135 , GTX1/4 <1, 
STX 66, dcSTX 39, GTX5 78 A 
[108] 
mAb ic- ELISA  
(GT-13a) 
 
Not tested Not tested dc-GTX2/3 68, C1/2 54, GTX1/4 8, STX 
6.9, neoSTX <1 A 
[107] 
DA 




scFv ELISA 156 ppb  Shellfish  Not reported [101] 
scFv ELISA 0.3 ppb  Shellfish  Not reported [100] 
mAb ELISA 0.15 ppb  Shellfish  Isodomoic acid -A 71, -B 1.3, -E < 1, -F 
1.4, -G < 1, -H < 1, KA < 1, L-AA < 1, L-




















Abbreviations: microsphere-based flow cytometery (MS-FC), 3-acetyl-DON (3-Ac-DON), 3-acetyl-DON (15-Ac-DON), L-phenylalanine (L-Phe), zearalenol (ZEL), 
zearalanol (ZAL), ochratoxin (OTA), nodularin (Nod), decarbamoyl-GTX2/3 (dc-GTX2/3), N-sulfocarbamoyl-GTX2/3 (C1/2), saxitoxin (STX), dihydrochloride (STXdi-
HCl), decarbamoyl saxitoxin (dcSTX), decarbamoyl neosaxitoxin (dcNEO), neosaxitoxin (neoSax), kainic acid (KA), L-aspartic acid (L-AA), L-glutamic acid (L-GA)  
 
Table 4 Comparison of recombinant antibody performance to a selection of animal-derived conventional antibodies in environmental or food samples. 
A adapted by reviewer to represent relative cross reactivity to GTX2/3   







To our knowledge every published rAb produced to hapten biotoxins have been generated using phage display 
technology despite the fact that the rAb with the highest known affinity to a hapten was produced using yeast 
display.  A yeast-displayed scFv exhibiting subnanomolar affinity to the model hapten fluorescein was affinity 
matured in vitro  resulting in creation of a “super antibody” with femtomolar (10-15 M) binding affinity similar 
to that of the streptavidin-biotin interaction [34, 172]. A significant limitation of phage display is the 
unpredictable expression of mammalian antibodies in bacterial expression systems commonly employed 
however eukaryotic systems such as yeast produce a higher ratio of functional antibody because they possess 
cellular mechanisms ensuring display of correctly folded rAb [173]. For this reason yeast display is considered a 
superior platform for surface displaying a fully representative functional rAb repertoire for affinity selection and 
post-production in vitro affinity maturation processes.  Yeast display has produced hapten-specific rAb with 
nanomolar (thiazole orange) to picomolar (tacrolimus) affinity [174] and would be an ideal platform for 
generating high affinity binders to hapten biotoxins. 
Due to the co-occurrence of multiple phycotoxins in shellfish or mycotoxin contaminations of plant materials 
the emphasis in biotoxin screening assays  has moved towards simultaneous detection of several toxins in a 
single sample [156, 175, 176].  Antibody microarrays offer the prospect of rapid multiplex detection of analytes 
and require only a fraction of antibody reagent used in conventional immunoassay formats (pL droplet 
compared to µl volumes for ELISA). The functional stability of conventional Abs in a microarray setting varies 
significantly but rAb have been found to constitute an excellent probe source for such applications. Some rAb-
based phage libraries (e.g. n-CoDeR, Table 2) have been validated to provide probes displaying excellent on-
chip performances all based on a single, fixed antibody scaffold which in some cases possess a shelf-life of over 
a year [177]. Other advantages are (1) rAb repertoires can be designed with affinity tags for immobilisation of 
antibodies to maximise antigen interactions, (2) their small size facilitates the production of high density arrays 
and (3) arrays based on a single, fixed scaffold means that all probes are homogenous (except for antigen-
binding sites)  which minimizes any probe-dependent assay variations. 
In most cases reviewed herein success of affinity selection of hapten-specific rAbs was evaluated 




valuable rAb clones. This “flashlight” approach opens the possibility of missing many highly valuable 
antibodies due to the workload required to screen every single clone. Automated robotic high-throughput 
screening [62] and next generation  sequencing (NGS) of antibody genes have demonstrated the way forward in 
this regard. Deep sequencing analysis has been successfully carried out on peptide [178] and naïve scFv libraries 
[179] and can identify paratopes of potential hapten binders as well as help eliminate false-positive hits using 
only sequencing data. Replacement of conventional randomly picked scFv phage ELISA screening with in depth 
NGS analysis  of CDR frequency from a scFv phage library following affinity selection retrieved the most 
potent target-specific scFv, some of which, were missed using classical in vitro screening [180].  With this in 
mind a low cost approach utilising open source software (AbMining ToolBox 
http://sourceforge.net/projects/abmining/) for H CDR3 deep sequencing outputs has recently been described and 
validated using a naïve and natural scFv repertoire [181]. Proteomics-based approaches marrying mass 
spectrometrical (LC-MS/MS) shotgun analysis of polyclonal serum antibodies (in particular HCDR3) produced 
following immunisation and V gene sequence database generated by NGS analysis of the same animals B cells 
has been used to rapidly identify heavily enriched populations of antigen-specific antibodies [182]. Such 
proteomics approaches avoid the often cumbersome technical and practical challenges involved in 
conventionally produced antigen-specific conventional and recombinant Abs and have resulted in the rapid 
production of recombinant mAbs with affinities surpassing that of the source pAb serum [183, 184].  
 
Conclusion 
The last two decades has seen the development of a number of rAb-based immunoassays for the rapid screening 
of hapten biotoxins in foods and environmental samples. The potential advantages of rAb over their 
conventional counterparts are as follows; (1) generating binders from naïve rAb repertoires circumvents the 
need for animal work in accordance with European legislation on animal protection [188], (2) the faster 
production pipelines (1-2 months from a naïve library) relative to conventional antibody production, (3) greater 
opportunities for improvement of rAb performance post-production by in vitro genetic manipulations, (4) 
haptens do not require the modifications (derivatives or conjugated to carrier molecules) necessary for animal 
immunisations in order to generate in vitro binders, (5) the antigen-driven inter-chain interaction of antibody V 
domains can be exploited in non-competitive immunoassays and, (6) rAb can be generated to extremely potent 




is not a single example where a conventional Ab-based assay has not been published with equivalent or superior 
sensitivity or specificity (Tables 5 and 6). A note of caution is highlighted in the case of AFB1, the biotoxin to 
which most rAb have been produced to date, where of the thirteen  AFB1-specific rAb-based immunoassays 
reported only two ELISAs [87, 120] and one SPR assay [90] were  successfully validated using a relevant food 
matrix. This suggests that AFB1 was used more as a model ligand to validate the ability of a phage display 
library to generate hapten-specific rAb than to produce an immunoanalytical platform for AFB1 detection in 
food and feeds. 
rAb possess several advantages over conventional Ab however most cases reviewed herein are 
produced from immunised animals thus necessitating animal work. The use of naïve natural and synthetic 
repertoires avoids animal use and can produce rAb in a shorter time period than the immune approach however 
affinities from these libraries are usually lower than those of immunised approach. It must also be noted that 
commercialised immunoassays employing rAbs isolated from commercially available naive phage display 
libraries can be subject to licensing fees and some companies have restricted access to their libraries to protect 
intellectual property rights (Table 2). On the whole, rAb technology provides great potential in enhancing 





Hapten biotoxin Conventional antibody Recombinant antibody 
Mycotoxins 
Aflatoxins Validated  commercial and “in house” pAb/mAb-based assays available 
capable of detecting sub-regulatory levels of 
-AFB1 
-total aflatoxins (AFB1+B2+G1+G2) 
-AFM1/M2 (milk) 
In a wide range of foods, feeds & cereals 
Two rAb-based ELISA and one SPR assays validated to detect AFB1 
in cereals 
One scFv SPR validated to detect AFB2 in nuts 
No rAb –based assays commercially available 
Tricothecenes (DON)  Validated  commercial and “in house” assays  available for DON testing 
in food, feed & drink 
scFv ELISA capable of detecting sub-regulatory levels of DON in 
wheat- not commercially available 
Fumonisins Validated  commercial and “in house”  assays available immunoassays  
for 
-FB1 
- total fumonisins (FB1,B2,B3) 
 in a wide range of cereals 
scFv ELISA capable of detecting  sub-regulatory levels of FB1 in 
wheat- not commercially available 
Ochratoxins Validated  commercially available and  “in house” assays capable of 
detecting sub-regulatory levels of OTA in wide range of foods, 
beverages, cereals and feeds 
 
VHH ELISA capable of detecting  sub-regulatory levels of OTA in 
beverages- not commercially available 
ZEN Validated  commercial available and  “in house” assays capable of 
detecting sub-regulatory levels of OTA in wide range of cereals and 
feeds 
scFv ELISA capable of detecting  sub-regulatory levels of ZEN in 




Aquatic & Marine Toxins 
 ASP toxins (DA) Validated  commercial available and  “in house” ELISAs capable of 
detecting sub-regulatory levels of DA in shellfish and water 
Two scFv ELISAs capable of detecting sub-regulatory levels of DA 
in shellfish- not commercially available 
Ciguatoxins (CTX) mAb-based “in house” ELISAs reported 
No commercially antibody-based assays available 
Fab-based assay possesses weak affinity for natural toxin 
PSP toxins (GTX2/3) Validated  pAb/mAb-based assays capable of detecting greater number 
of PSP toxins  at or below regulatory limit in shellfish  
scFv OS-ELISA capable of detecting 4 PSP toxins at regulatory limit 
in shellfish- not commercially available 
Microcystins Validated  commercial and “in house” assays available for detection of 
sub-regulatory levels of microcystins 
Validated  “in house” ELISAs- not commercially available 
Commercially available LFD available 
 
Table 5. Summary of the progress of recombinant (rAb) and conventional Ab (pAb or mAb)-based immunoassays in detecting hapten biotoxins in food and environmental 
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